Announcements Trials
Browse Landscape

Phase

Phase 2 22Phase NA 3Phase EARLY_PHASE1 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 16Thoracic 4Lymphoid 3CNS 2Breast 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1

Conditions

Osteosarcoma 1

Interventions

Temozolomide 33Radiotherapy 32pembrolizumab 18Cyclophosphamide 18Irinotecan 16Gemcitabine 16Doxorubicin 16Nivolumab 11Docetaxel 11Sirolimus 10Imatinib Mesylate 10Ifosfamide 10Filgrastim 10Radiation 9Bevacizumab 9Vincristine 8Carboplatin 8pazopanib 7Everolimus 7temsirolimus 6atezolizumab 6Peripheral Blood Stem Cell Transplantation 6Etoposide 6fludarabine phosphate 5Vorinostat 5Specimen Handling 5Radiotherapy, Conformal 5PM 01183 5Ipilimumab 5Erlotinib Hydrochloride 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × apatinib × Sarcoma × Clear all
NCT07479732 2026-03-18

Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma

Peking University People's Hospital

Phase 1/2 Recruiting
56 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡